SECONDARY HYPERPARATHYROIDISM
Clinical trials for SECONDARY HYPERPARATHYROIDISM explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug SHR6508 aims to tame hormone imbalance in dialysis patients
Disease control CompletedThis study tested a new drug called SHR6508 in 498 adults on hemodialysis who have secondary hyperparathyroidism, a condition where the parathyroid glands make too much hormone. The drug is given during dialysis and was compared to an existing oral medication, cinacalcet. The goa…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug aims to tame parathyroid glands in dialysis patients
Disease control CompletedThis study tested a drug called PLS240 in 412 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). Participants received either PLS240 or a placebo intravenously three times a week for 27 weeks, followed by …
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated Jun 26, 2026 14:53 UTC
-
New drug aims to tame parathyroid glands in dialysis patients
Disease control CompletedThis study tested a drug called PLS240 in 362 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). Participants received either PLS240 or a placebo during dialysis three times a week for 27 weeks, followed b…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC
-
Tiny study tracks kidney Drug's exit route in dialysis patients
Knowledge-focused CompletedThis completed Phase 1 study looked at how a radioactive form of the drug SHR6508 is processed and eliminated in 5 Chinese adults on hemodialysis who have secondary hyperparathyroidism. The main goal was to measure how much radioactivity ends up in urine and stool, and to identif…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC